$BIEL - BioElectronics Technology Primed to Meet Patients’ Need

BioElectronics Technology Primed to Meet Patients’ Need

OTC Pink: BIEL Shares Issues  11.4 Billion 52 Week Range .0003- 0.0025 Products Sold 1+ Million Devices The Right Products and Investment: OTC Pink: BIEL BioElectronics Corporation (www.bielcorp.com) develops, manufacturers, markets and sells consumers medical electronics that reduce swelling and relives pain. BioElectronics has developed and patented an exceptionally effective, affordable, and 100% safe analgesic to dominate the over-the-counter market for musculoskeletal pain, and provide an adjunctive or alternative to narcotic drug therapy.

Investors should know that there is a perfect storm of unmet consumer needs coalescing into a major opportunity that BioElectronics Corporation is ideally suited to capture. Several large pharmaceutical companies like Glaxo Smith Kline (GSK), Bayer and Sanofi are recognizing both the limitations of drug-only therapy and the potential of bioelectronic devices to relieve pain without side effects and have recently introduced their own bioelectronic research products and programs.

BioElectronics Corporation is the leading commercial stage company in the field of non-invasive consumer electroceutical medical devices. Its small light wearable devices produce a pulsating electromagnetic field that affects cells and nerves to treat acute and chronic pain as well as to promote wound healing by a process called neuromodulation. The products are approved for OTC sale in the European Union, Canada, Australia, Singapore, etc. and pending US over-the-counter market clearance for relief of musculoskeletal pain. The 720-hour device with an on/off switch retails for approximately $30.00, or 4 cents per hour of therapy, which provides an extraordinary cost/benefit.

Chronic Pain One-third of the population suffers from chronic pain, which is more than diabetes, heart disease, and cancer combined.

The Most Important Pain Relief News in 47 Years

Pain itself often modifies the way the central nervous system works so that a patient actually becomes more sensitive and gets more pain with less provocation. That sensitization is called “central sensitization” because it involves changes in the central nervous system in particular - the brain and the spinal cord. It is well understood that the extent of tissue injury does not explain the level of pain, and chronic pain can be maintained even after an initial injury has healed.

ActiPatch® stimulates sub-sensory afferent nerves to dampen the pain signals a process known as neuromodulation. Ken McLeod’s, PhD. Director of Clinical Science and Engineering Research, Binghamton University State University of New York short video explains how the technology and ActiPatch work at http://actipatch.com/why-actipatch/.

Demonstrated Marketability to Consumers the Company’s Try & Tell sales and marketing program won this year’s OTC Bulletin “Best OTC Marketing Campaign on a Small Budget” award. Current chronic pain therapies do not meet the need for chronic pain relief and sufferers are skeptical. To overcome the skepticism and accelerate product acceptance, we promote a discounted 7-Day Trial device without an on/off switch. 65% of testers averaged a 57% reduction in pain and said they “intended” to or would “maybe” purchase and 80% did purchase an average of 1.75 devices within 90-days. After one year, the users purchased an average of 2.7 devices.

Exceptional Consumer Acceptance the Medical Journal Pain Management published our 5,000+ survey results A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35, reported 2/3 of participants had more than 57% pain relief and the following long-term results:

•               2/3 (including opioid users) reported moderate to complete elimination of pain medications;

•               2/3 reported improved sleep;

•               3/4 reported increased physical activity; and,

•               4/5 a substantial improvement in overall quality of life.

ActiPatch® Musculoskeletal Pain Therapy

Meets The Dire Need for Drug-free Pain Relief

ActiPatch Customers in the UK Say It for Themselves Links to https://youtu.be/oeiLlvY2GUQ

Ongoing clinical research will enable treatment of new indications and open new markets:

·         Aarhus Univ. Hospital, Denmark (Venous Ulcer Wound Healing);

·         Univ. Hospital Ghent, Belgium (Bilateral Hernia Surgery); and,

·         Chronic Back Pain, Oxford University Hospital

Management Team

Richard Staelin, Ph. D. Chairman of the Board takes an active role in the strategic planning for the Company

Andrew J. Whelan President oversees day-to-day operations

Mary K. Whelan Director is the sister of President an early investor, former Marketing VP AT&T and Lucent 

William Monn Vice President of Production is responsible for product production and regulatory compliance

Ian Rawe, Ph.D. Director of Clinical Research manages clinical trials and research

John Martinez Director of Engineering is responsible for product design and functionality

Sree N. Koneru, Ph. D Director of Electroceutical Research conducts biomedical research and new product development